Through this role as an RyR inhibitor, flecainide has been shown, in a mouse model of CPVT, to prevent ventricular tachycardia by suppressing spontaneous Ca2+ release. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.